The mechanism by which L-glutamine (LGln) inhibits the release of endothelium-derived relaxing factor from bovine aortic cultured endothelial cells was investigated. Iyase. L-Gln also inhibited the generation of L-Arg by the monocyte-macrophage cell line J774 but had no effect on the conversion of L-Cit to L-Arg by these cells. As the release of endothelium-derived relaxing factor from cultured and noncultured endothelial cells is limited by the availability of L-Arg, endogenous L-Gln may play a regulatory role in the biosynthesis of endothelium-derived relaxing factor. Vascular endothelial cells (1) and stimulated macrophages (2) generate nitric oxide (NO) or a chemically related molecule (3) through the oxidative metabolism of one of the guanidino nitrogens of the amino acid L-arginine (L-Arg). The release of NO derived from L-Arg accounts for the vasorelaxant properties of endothelium-derived relaxing factor (EDRF) and the cytotoxicity of activated macrophages (1, 4, 5). The availability of L-Arg analogues as NO synthase inhibitors and the unique pharmacologic profile of NO has enabled its biosynthesis from L-Arg to be demonstrated in many cell types including polymorphonuclear leukocytes (6), astrocytes (7), hepatocytes (8), mast cells (9), platelets (10), adrenal (11) and brain (12, 13) tissue(s), and possibly smooth muscle cells (14). Some information is available regarding the metabolism of L-Arg by intact cells or semipurified preparations from endothelial cells (15), cytotoxic macrophages (2), or adrenal (11) or brain (12) tissues, but little is known about the regulation and sources of intracellular L-Arg required for NO biosynthesis.
Iyase. L-Gln also inhibited the generation of L-Arg by the monocyte-macrophage cell line J774 but had no effect on the conversion of L-Cit to L-Arg by these cells. As the release of endothelium-derived relaxing factor from cultured and noncultured endothelial cells is limited by the availability of L-Arg, endogenous L-Gln may play a regulatory role in the biosynthesis of endothelium-derived relaxing factor. Vascular endothelial cells (1) and stimulated macrophages (2) generate nitric oxide (NO) or a chemically related molecule (3) through the oxidative metabolism of one of the guanidino nitrogens of the amino acid L-arginine (L-Arg). The release of NO derived from L-Arg accounts for the vasorelaxant properties of endothelium-derived relaxing factor (EDRF) and the cytotoxicity of activated macrophages (1, 4, 5) . The availability of L-Arg analogues as NO synthase inhibitors and the unique pharmacologic profile of NO has enabled its biosynthesis from L-Arg to be demonstrated in many cell types including polymorphonuclear leukocytes (6) , astrocytes (7), hepatocytes (8) , mast cells (9) , platelets (10), adrenal (11) and brain (12, 13) tissue(s), and possibly smooth muscle cells (14) . Some information is available regarding the metabolism of L-Arg by intact cells or semipurified preparations from endothelial cells (15) , cytotoxic macrophages (2), or adrenal (11) or brain (12) tissues, but little is known about the regulation and sources of intracellular L-Arg required for NO biosynthesis.
We have demonstrated (16) that cultured endothelial cells, deprived of extracellular L-Arg for 24 hr, when transferred to Krebs' solution, release increasing quantities of EDRF concomitant with the generation of L-Arg from an intracellular source, implying that the availability of intracellular L-Arg is rate-limiting for EDRF biosynthesis. While investigating the mechanisms by which endothelial cells generate L-Arg (17), we discovered a constituent of the culture medium inhibited both the generation of L-Arg and the release of EDRF (16, 18) . This report describes the characterization of this factor, the amino acid L-glutamine (L-Gln), and suggests a biochemical mechanism for its inhibitory action on EDRF biosynthesis. Preparation of Endothelial Cell Homogenates. Endothelial cells (3 ml) grown in Arg-free MEM for 24 hr were washed 5-10 times with Krebs' buffer (9 vol) and lysed by five cycles of freezing in liquid nitrogen and thawing and further homogenized with a glass-glass homogenizer. Ice-cold Krebs' buffer (1.5 ml) was added and the homogenate was centrifuged for 10 min at 1200 x g and 4°C. The supernatant was either used directly or frozen in liquid nitrogen and stored at -200C.
MATERIALS AND METHODS
To assay the conversion of various amino acids to L-Arg, 100 ,ul of the supernatant was added to Krebs' buffer (total volume, 250 ,ul) and either extracted directly (0-min sample) with methanol (5 vol) or incubated for 60 min at 37°C. Incubations were terminated by adding 1.25 ml of ice-cold methanol and samples were processed for HPLC analysis as described above.
Cultured J774 Cells. The mouse monocyte-macrophage cell line J774.2 (ECACC No. 85011428) was obtained from the European Collection of Animal Cell Cultures (Salisbury, U.K.), certified to be mycoplasma-free at the time of purchase. The cells were cultured as a semisuspension in DMEM containing 4 mM L-Gln and 10% FCS. After reaching 1-2 x 106 cells per ml, the cells were cultured in Arg-free MEM without FCS for 24 hr. They were then washed five times with Krebs' buffer (25 ml) and 1 x 106 cells in 100 ,l were either directly extracted with 500 ,l of methanol or incubated in Krebs' solution (total volume, 1 ml) for 60 min at 370C. The cells were centrifuged for 2 min at 800 x g and resuspended in 100 ,u of Krebs' buffer to which methanol (500 ,ul) was added. Samples were processed for HPLC or TLC analysis as described above.
Statistics. All data are presented as mean ± SEM. (Fig. 3) .
Other Effects of L-Gln. L-Gln (200 ,M) also inhibited the increase in L-Arg observed in nondepleted endothelial cells (95.9 ± 2.1% inhibition; n = 4; P < 0.05), when these cells were transferred to Krebs' solution. There was no change in intracellular ammonia levels (103.8 ± 7.2% compared with a 60-min control; n = 3) in the presence of L-Gln (200 ,M), but there was a significant increase (156.2 ± 8.8%; n = 3; P < 0.01) in the release of ammonia, indicating a metabolism of L-Gln to L-glutamic acid and ammonia. Similar changes in ammonia (determined as described in ref. 17) (MeArg), an inhibitor of EDRF biosynthesis, which is converted to L-Cit and subsequently L-Arg by endothelial cells (21) , was also inhibited by L-Gln (41% inhibition from 308.8 + 90.9% to 182.6 ± 58.3% of 60 min control; n = 3).
To examine whether L-Gln was interfering with the overall synthesis of L-Arg (Fig. 1) (Fig. 5) .
The generation of L-Arg from L-Cit may arise by the formation of L-argininosuccinate (L-Argsucc) as an intermediate (17) . Therefore, the effect of L-Gln (200 ,uM) on the conversion of L-Argsucc (100 ,uM) to L-Arg was investigated by using endothelial cell homogenates, for L-Argsucc appears to be unable to cross the cell membrane (17) . Indeed, L-Argsucc was converted to L-Arg by homogenates (4.6 ± 1.8% conversion after 60 min; n = 5), but this reaction was not inhibited by L-Gln (4.2 ± 1.6% conversion; n = 5). (17) in endothelial cells may, therefore, reflect a specific control mechanism for the generation of L-Arg and, hence, the biosynthesis of EDRF. However, the inability of L-Gln to inhibit the conversion of L-Cit to L-Arg by nonstimulated J774 cells may simply reflect the low capacity of J774 cells to generate NO under these conditions (28) .
We conclude that in cultured endothelial cells L-Gln inhibits the generation of L-Arg and the release of EDRF, in part by interfering with the recycling of L-Cit to L-Arg during EDRF biosynthesis (17) . Moreover, the inhibition of both of these events by L-Gln emphasizes the possibility that the availability of L-Arg is under strict metabolic control and, therefore, rate limiting for the biosynthesis of EDRF.
